Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 18, 2024 /PRNewswi ...

NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ps ...

SAN DIEGO, Dec. 16, 2024 /PRNewswire/ -- Robbins LLP announces that a class action was filed on behalf of all investors who purchased or otherwise acquired Cassava Sciences, Inc. (NASDAQ: SAVA) securities between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Invest ...

NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=116401&from=4CLASS PERIOD: Februar ...

NEW YORK, Dec. 13, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2025.So what: If you purchased Cassava securities during the C ...

Cassava Sciences’ (SAVA) stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study for Alzheimer’s disease (AD).SAVA releases top-line results from the ReThink-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive or functional decline in AD patients when compared to placebo over a 52-week period, ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 83.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicato ...

Cassava Sciences SAVA stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock’s crash Sunday night.What Happened: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, sending shares significantly lower to start the trading week.The company sai ...

KEY TAKEAWAYSCassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug aimed at treating Alzheimer’s disease failed a late-stage study.The drug was aimed at treating patients with mild-to-moderate Alzheimer’s.A second late-stage trial for the drug Simufilam has also been discontinued. Cassava Sciences (SAVA) shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

Cassava Sciences Inc. SAVA stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease.The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints.In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant financial and emotional stakes.The co-primary endpoints were the change in cog ...